中国中医药信息杂志
中國中醫藥信息雜誌
중국중의약신식잡지
CHINESE JOURNAL OF INFORMATION ON TRADITIONAL CHINESE MEDICINE
2014年
9期
61-63
,共3页
曹焕敏%成秀梅%王晓松%王蓓
曹煥敏%成秀梅%王曉鬆%王蓓
조환민%성수매%왕효송%왕배
愈肾合剂%糖尿病肾病%内源性一氧化碳%血红素氧合酶-1%血红素氧合酶-2%大鼠
愈腎閤劑%糖尿病腎病%內源性一氧化碳%血紅素氧閤酶-1%血紅素氧閤酶-2%大鼠
유신합제%당뇨병신병%내원성일양화탄%혈홍소양합매-1%혈홍소양합매-2%대서
Yushen Heji%diabetic nephropathy%carbon monoxide%HO-1%HO-2%rats
目的:观察愈肾合剂对糖尿病模型大鼠肾脏组织血红素氧合酶(HO)-1、HO-2的影响,探讨其治疗糖尿病肾病作用机制。方法 SD大鼠随机分为正常组、模型组、对照组、治疗组。采用皮下注射链脲佐菌素法复制模型,对照组和治疗组给予相应药物灌胃,正常组和模型组灌胃等量蒸馏水。给药8周后,收集尿液测定24 h尿蛋白(Upro)、尿肌酐(Ucr),断头取血测定一氧化碳(CO)、尿素氮(BUN)、血肌酐(Scr),采用免疫组织化学法检测肾脏组织HO-1、HO-2的表达。结果与正常组比较,模型组大鼠BUN、24 h Upro、Scr升高,肌酐清除值(Ccr)、血浆 CO 降低,肾脏组织的 HO-1、HO-2表达明显减弱(P<0.01);与模型组比较,治疗组和对照组BUN、24 h Upro、Scr明显下降,Ccr、血浆CO活性升高,肾脏组织的HO-1、HO-2表达明显增强(P<0.05,P<0.01);与对照组比较,治疗组24 h Upro降低,血浆CO活性升高,肾脏组织HO-1、HO-2表达明显增强(P<0.05,P<0.01)。结论愈肾合剂对糖尿病肾病大鼠有一定的治疗作用,可能是通过HO/CO系统实现的。
目的:觀察愈腎閤劑對糖尿病模型大鼠腎髒組織血紅素氧閤酶(HO)-1、HO-2的影響,探討其治療糖尿病腎病作用機製。方法 SD大鼠隨機分為正常組、模型組、對照組、治療組。採用皮下註射鏈脲佐菌素法複製模型,對照組和治療組給予相應藥物灌胃,正常組和模型組灌胃等量蒸餾水。給藥8週後,收集尿液測定24 h尿蛋白(Upro)、尿肌酐(Ucr),斷頭取血測定一氧化碳(CO)、尿素氮(BUN)、血肌酐(Scr),採用免疫組織化學法檢測腎髒組織HO-1、HO-2的錶達。結果與正常組比較,模型組大鼠BUN、24 h Upro、Scr升高,肌酐清除值(Ccr)、血漿 CO 降低,腎髒組織的 HO-1、HO-2錶達明顯減弱(P<0.01);與模型組比較,治療組和對照組BUN、24 h Upro、Scr明顯下降,Ccr、血漿CO活性升高,腎髒組織的HO-1、HO-2錶達明顯增彊(P<0.05,P<0.01);與對照組比較,治療組24 h Upro降低,血漿CO活性升高,腎髒組織HO-1、HO-2錶達明顯增彊(P<0.05,P<0.01)。結論愈腎閤劑對糖尿病腎病大鼠有一定的治療作用,可能是通過HO/CO繫統實現的。
목적:관찰유신합제대당뇨병모형대서신장조직혈홍소양합매(HO)-1、HO-2적영향,탐토기치료당뇨병신병작용궤제。방법 SD대서수궤분위정상조、모형조、대조조、치료조。채용피하주사련뇨좌균소법복제모형,대조조화치료조급여상응약물관위,정상조화모형조관위등량증류수。급약8주후,수집뇨액측정24 h뇨단백(Upro)、뇨기항(Ucr),단두취혈측정일양화탄(CO)、뇨소담(BUN)、혈기항(Scr),채용면역조직화학법검측신장조직HO-1、HO-2적표체。결과여정상조비교,모형조대서BUN、24 h Upro、Scr승고,기항청제치(Ccr)、혈장 CO 강저,신장조직적 HO-1、HO-2표체명현감약(P<0.01);여모형조비교,치료조화대조조BUN、24 h Upro、Scr명현하강,Ccr、혈장CO활성승고,신장조직적HO-1、HO-2표체명현증강(P<0.05,P<0.01);여대조조비교,치료조24 h Upro강저,혈장CO활성승고,신장조직HO-1、HO-2표체명현증강(P<0.05,P<0.01)。결론유신합제대당뇨병신병대서유일정적치료작용,가능시통과HO/CO계통실현적。
Objective To observe the effects of Yushen Heji on expressions of Heme Oxygenase (HO-1) and HO-2 in kidney of diabetic rats;To explore its mechanism in diabetic nephropathy. Methods SD rats were randomly divided into normal group, model group, control group and treatment group. Models were duplicated by subcutaneous injection STZ. Control group and treatment group were given gavage with related medicine, while normal group and model group were given gavage with the same amount of distilled water. Eight weeks later, the urine of rats was collected to detect the 24 h Upro and Ucr;the rats were sacrificed to detect the levels of CO, BUN and Scr;the kidneys were harvested for observing the expressions of HO-1 and HO-2 by immunohistochemistry.Results Compared with normal group, the contents of BUN, 24 h Upro and Scr all increased in model group;Ccr and plasma CO decreased;the expressions of HO-1 and HO-2 in kidney tissues were obviously reduced (P<0.01). Compared with model group, the contents of BUN, 24 h Upro and Scr all obviously decreased in treatment group and control group;Ccr and plasma CO increased;the expressions of HO-1 and HO-2 in kidney tissues obviously increased (P<0.05,P<0.01). Compared with control group, the contents of 24 h Upro decreased in treatment group;plasma CO increased;the expressions of HO-1 and HO-2 in kidney tissues obviously increased (P<0.05,P<0.01).Conclusion Yushen Heji has therapeutic effect on diabetic nephropathy rats, which may related with HO/CO system.